Letrozole — Discount Pricing

Other medications in Hormones

• Medroxyprogesterone
• Norethindrone
• Octreotide
• Progesterone
• Tamoxifen
• Testosterone Cypionate
• Testosterone Gel
• Anastrozole

About Letrozole

Letrozole is a crucial medication often prescribed for hormone-receptor-positive breast cancer in postmenopausal women and, in some cases, for infertility. Understanding its role and how to manage its cost is key. With TheDrugClub, you can access significant savings on letrozole, helping to make your essential treatments more affordable and accessible.

Letrozole is primarily known for its role in treating hormone-receptor-positive breast cancer in postmenopausal women. It's used both as an initial treatment and after other therapies to reduce the risk of recurrence. Beyond cancer, letrozole has also found utility in reproductive medicine, often prescribed off-label to induce ovulation in women experiencing infertility, particularly those with polycystic ovary syndrome (PCOS). Its versatility makes it a valuable medication for several critical health conditions.

Letrozole belongs to a class of drugs called aromatase inhibitors. Its mechanism of action involves blocking the enzyme aromatase, which is responsible for converting androgens (male hormones) into estrogens (female hormones) in various tissues throughout the body, including fat, muscle, and breast tissue. By inhibiting aromatase, letrozole significantly lowers estrogen levels in the body. For hormone-receptor-positive breast cancer, this reduction in estrogen starves cancer cells that rely on estrogen to grow, thereby slowing or stopping their proliferation. In fertility treatment, by lowering estrogen, it can trick the body into producing more follicle-stimulating hormone (FSH), which stimulates ovulation.

The cost of letrozole can vary considerably. Factors influencing the price include whether you're prescribed the brand-name version (Femara®

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Letrozole is approved for (FDA label)

Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 ) 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.

Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Letrozole (FDA label)

2.5 mg tablets: Yellow colored, film-coated, round shaped tablets debossed with one side 'N' and other side 'L'. 2.5 mg tablets. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Letrozole (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling. Bone effects [see Warnings and Precautions (5.1) ] Increases in cholesterol [see Warnings and Precautions (5.2) ] Fatigue and Dizziness [see Warnings and Precautions (5.4) ] The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc., at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Letrozole (FDA label)

Pregnancy: Letrozole can cause fetal harm [see Use in Specific Populations (8.1) ] . Known hypersensitivity to the active substance, or to any of the excipients [see Adverse Reactions (6) ] . Pregnancy. ( 4 ) Known hypersensitivity to the active substance, or to any of the excipients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3cc750a5-cc88-4b42-b4ab-a87e760f291d. SPL document ID: f187c05f-b55e-47f9-9c42-ee3640d28bfd. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.